Breaking News
Bookmark this page to stay up to date on the latest advances in juvenile dermatomyositis and juvenile polymyositis research and treatments, as well as updates on our support network for JM families.
Cabaletta Bio Presents Promising Early Data for CAR-T in Myositis
New research presented at the American College of Rheumatology’s annual conference points to a major step forward in autoimmune disease treatment. Cabaletta Bio shared encouraging data from its RESET clinical trials, which are testing a groundbreaking CAR-T therapy designed to “reset” the immune system and bring lasting remission without ongoing immune-suppressing drugs.
Read the full story to learn how these early results could shape the future of treatment for juvenile myositis and other autoimmune diseases…
Cure JM Announces Five New Grants to Help Kids and Families
As we continue accelerating work on CAR-T therapy, JAK inhibitors, and other breakthrough opportunities, we are thrilled to announce five additional grants that will help families in new ways. Our latest grant cycle drew an outstanding group of fifteen proposals, demonstrating the strength and quality of research underway across our community. After a rigorous review with third-party advisors, Cure JM Foundation leadership selected three scientific projects, one mental health project, and one fellowship award for funding…
New Treatments
Cure JM continues to advance new treatment options by investing in research that targets the underlying immune drivers of juvenile myositis. Our focus remains on therapies that are more precise, more effective, and safer for children over the long term. This includes support for studies exploring biologics, small molecule therapies, and emerging immune-based approaches.
We are actively supporting clinical trials and translational research that help move discoveries from the lab into patient care. By partnering with leading researchers and clinicians, Cure JM helps reduce barriers to trial participation and accelerates the pace at which promising treatments can be evaluated in children and young adults.
Equally important, Cure JM works to ensure families and clinicians have access to clear and timely information about new treatment developments. Through educational updates, conference sessions, and clinician collaboration, we help translate complex research into practical knowledge that supports informed care decisions.
A new study published in Annals of Rheumatic Diseases used Cure JM–supported biosamples to identify protein patterns linked to ongoing inflammation, blood vessel involvement, and differences among juvenile dermatomyositis (JDM) subtypes. The findings suggest current lab tests may not fully capture disease activity and point toward more personalized ways to monitor and treat JDM.
Cure JM’s Clinical Care Network strengthens access to expert care by connecting families with clinics that have deep experience in juvenile myositis. This network helps ensure that children receive timely diagnosis, appropriate monitoring, and evidence based treatment regardless of where they live.
Through the CCN, Cure JM promotes shared standards of care and collaboration across sites. Clinicians participate in ongoing education, data sharing, and peer connection that improve consistency and quality of care for patients across the country.
The network also serves as a foundation for research and clinical trials, making it easier for families to learn about opportunities to participate. By integrating care and research, the CCN plays a critical role in improving outcomes today while advancing better treatments for the future.
Parent and Family Support
Families are at the center of everything Cure JM does. We provide education and resources that help parents and caregivers understand the disease, navigate treatment decisions, and manage the daily realities of juvenile myositis.
Cure JM also fosters meaningful peer connection so families never feel alone. Through support programs, events, and community outreach, parents can connect with others who understand their experiences and can share practical guidance and encouragement.
As children grow, Cure JM supports the entire family across each stage of the journey, from diagnosis through adolescence and into adulthood. By listening to families and responding to their evolving needs, we ensure our programs remain relevant, compassionate, and grounded in real world experience.
